Track disease progression in Parkinson
- Trial ID
- NCT07353463
- Official Title
- Shanghai Clinical Cohort - Parkinson's Disease (Reserve)
- Goal
- Track disease progression in Parkinson
- Status
- RECRUITING
- Sponsor
- Ruijin Hospital
- Study Type
- OBSERVATIONAL
- Enrollment
- 700 participants
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy
Plain-Language Summary
The goal is to build a large Shanghai cohort to find fluid and imaging biomarkers that help distinguish Parkinson's disease from multiple system atrophy and to track how each condition progresses. Participants give blood, saliva and optionally cerebrospinal fluid, and have MRI and PET/SPECT scans plus detailed motor and nonmotor assessments so researchers can link protein markers, genetics, and brain imaging patterns to symptoms and progression. The protocol is observational, so usual treatments like levodopa are not changed while data are collected. Eligible are adults diagnosed with PD by the Chinese 2016 criteria or clinically probable MSA by the 2022 consensus who can give informed consent and tolerate samples and imaging; people with unclear diagnoses, major brain lesions, severe psychiatric illness, serious organ failure, or inability to complete assessments are excluded.
Locations
- Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to build a large Shanghai cohort to find fluid and imaging biomarkers that help distinguish Parkinson's disease from multiple system atrophy and to track how each condition progresses. Participants give blood, saliva and optionally cerebrospinal fluid, and have MRI and PET/SPECT scans plus detailed motor and nonmotor assessments so researchers can link protein markers, genetics, and brain imaging patterns to symptoms and progression. The protocol is observational, so usual treatments like levodopa are not changed while data are collected. Eligible are adults diagnosed with PD by the Chinese 2016 criteria or clinically probable MSA by the 2022 consensus who can give informed consent and tolerate samples and imaging; people with unclear diagnoses, major brain lesions, severe psychiatric illness, serious organ failure, or inability to complete assessments are excluded.
- Who can participate?
- Eligibility criteria vary. Check the full listing on ClinicalTrials.gov for detailed inclusion and exclusion criteria.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 9 months.